Derivation Web · source_3def4957dd22487e

source · application/json

source_3def4957dd22487e

sha256 d38c1a03faa5448195ac8d61273d65837c5d278be3b527196bea0afaf9bf7fa9

by researka:v2 · 2026-06-22 18:18:33.504072+04:00

{"publication_id": "2b3d1eb0-8efe-4468-b234-8a534f83b06b", "traces": [{"candidate_sources": [{"doi": "10.1155/jobe/3442754", "study": "Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration", "url": "https://doi.org/10.1155/jobe/3442754"}, {"doi": "10.1186/s12933-023-01800-z", "study": "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study", "url": "https://doi.org/10.1186/s12933-023-01800-z"}, {"doi": "10.1186/s12933-025-02915-1", "study": "Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes", "url": "https://doi.org/10.1186/s12933-025-02915-1"}, {"doi": "10.1016/j.metop.2024.100283", "study": "Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study", "url": "https://doi.org/10.1016/j.metop.2024.100283"}, {"doi": "10.1177/17562864241281903", "study": "Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis", "url": "https://doi.org/10.1177/17562864241281903"}], "claim": "Evidence-honesty note: 27/52 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. 50/52 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.", "claim_id": "claim_1"}, {"candidate_sources": [{"doi": "10.1155/jobe/3442754", "study": "Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration", "url": "https://doi.org/10.1155/jobe/3442754"}, {"doi": "10.1186/s12933-023-01800-z", "study": "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study", "url": "https://doi.org/10.1186/s12933-023-01800-z"}, {"doi": "10.1186/s12933-025-02915-1", "study": "Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes", "url": "https://doi.org/10.1186/s12933-025-02915-1"}, {"doi": "10.1016/j.metop.2024.100283", "study": "Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study", "url": "https://doi.org/10.1016/j.metop.2024.100283"}, {"doi": "10.1177/17562864241281903", "study": "Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis", "url": "https://doi.org/10.1177/17562864241281903"}], "claim": "We conducted an AI-assisted structured evidence synthesis with a per-claim audit trail, in which each cited finding is linked to a source and an outcome class; we did not invoke preclinical or surrogate evidence to substitute for direct human longevity data, following the methodological caution of Ioannidis 2005 that surrogate endpoint associations do not guarantee hard-outcome validity.", "claim_id": "claim_2"}, {"candidate_sources": [{"doi": "10.1155/jobe/3442754", "study": "Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration", "url": "https://doi.org/10.1155/jobe/3442754"}, {"doi": "10.1186/s12933-023-01800-z", "study": "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study", "url": "https://doi.org/10.1186/s12933-023-01800-z"}, {"doi": "10.1186/s12933-025-02915-1", "study": "Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes", "url": "https://doi.org/10.1186/s12933-025-02915-1"}, {"doi": "10.1016/j.metop.2024.100283", "study": "Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study", "url": "https://doi.org/10.1016/j.metop.2024.100283"}, {"doi": "10.1177/17562864241281903", "study": "Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis", "url": "https://doi.org/10.1177/17562864241281903"}], "claim": "Body-composition signals are no less ambiguous, because the canonical sarcopenia grip-strength cutoffs of 27 kg for men and 16 kg for women (Cruz-Jentoft 2019) and the WHO 2000 obesity threshold of 30 kg/m2 are the very benchmarks the GLP-1 claim must respect, and Effect of Oral Semaglutide 2026 and Ghanim 2024 provide only direct or null evidence on lean mass preservation, not longevity per se.", "claim_id": "claim_3"}, {"candidate_sources": [{"doi": "10.1155/jobe/3442754", "study": "Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration", "url": "https://doi.org/10.1155/jobe/3442754"}, {"doi": "10.1186/s12933-023-01800-z", "study": "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study", "url": "https://doi.org/10.1186/s12933-023-01800-z"}, {"doi": "10.1186/s12933-025-02915-1", "study": "Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes", "url": "https://doi.org/10.1186/s12933-025-02915-1"}, {"doi": "10.1016/j.metop.2024.100283", "study": "Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study", "url": "https://doi.org/10.1016/j.metop.2024.100283"}, {"doi": "10.1177/17562864241281903", "study": "Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis", "url": "https://doi.org/10.1177/17562864241281903"}], "claim": "Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.", "claim_id": "claim_4"}, {"candidate_sources": [{"doi": "10.1155/jobe/3442754", "study": "Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration", "url": "https://doi.org/10.1155/jobe/3442754"}, {"doi": "10.1186/s12933-023-01800-z", "study": "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study", "url": "https://doi.org/10.1186/s12933-023-01800-z"}, {"doi": "10.1186/s12933-025-02915-1", "study": "Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes", "url": "https://doi.org/10.1186/s12933-025-02915-1"}, {"doi": "10.1016/j.metop.2024.100283", "study": "Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study", "url": "https://doi.org/10.1016/j.metop.2024.100283"}, {"doi": "10.1177/17562864241281903", "study": "Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis", "url": "https://doi.org/10.1177/17562864241281903"}], "claim": "This synthesis evaluates evidence on GLP-1 longevity across 52 included source papers and 1577 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, indirect interventional hard-endpoint evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.", "claim_id": "claim_5"}, {"candidate_sources": [{"doi": "10.1155/jobe/3442754", "study": "Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration", "url": "https://doi.org/10.1155/jobe/3442754"}, {"doi": "10.1186/s12933-023-01800-z", "study": "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study", "url": "https://doi.org/10.1186/s12933-023-01800-z"}, {"doi": "10.1186/s12933-025-02915-1", "study": "Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes", "url": "https://doi.org/10.1186/s12933-025-02915-1"}, {"doi": "10.1016/j.metop.2024.100283", "study": "Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study", "url": "https://doi.org/10.1016/j.metop.2024.100283"}, {"doi": "10.1177/17562864241281903", "study": "Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis", "url": "https://doi.org/10.1177/17562864241281903"}], "claim": "The corpus contains 2 direct clinical sources, 50 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.", "claim_id": "claim_6"}, {"candidate_sources": [{"doi": "10.1155/jobe/3442754", "study": "Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration", "url": "https://doi.org/10.1155/jobe/3442754"}, {"doi": "10.1186/s12933-023-01800-z", "study": "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study", "url": "https://doi.org/10.1186/s12933-023-01800-z"}, {"doi": "10.1186/s12933-025-02915-1", "study": "Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes", "url": "https://doi.org/10.1186/s12933-025-02915-1"}, {"doi": "10.1016/j.metop.2024.100283", "study": "Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study", "url": "https://doi.org/10.1016/j.metop.2024.100283"}, {"doi": "10.1177/17562864241281903", "study": "Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis", "url": "https://doi.org/10.1177/17562864241281903"}], "claim": "The thesis is: Across 52 curated reference papers, the evidence base for Glp 1 shows a context-dependent profile. Positive signals appear in: longevity, mortality survival. Negative signals appear in: cardiometabolic, contextual other. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Glp 1 anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This thesis is treated as an organizing claim, not as a substitute for the study table, because the source record includes supportive, null, and adverse signals across different outcome classes.", "claim_id": "claim_7"}, {"candidate_sources": [{"doi": "10.1155/jobe/3442754", "study": "Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration", "url": "https://doi.org/10.1155/jobe/3442754"}, {"doi": "10.1186/s12933-023-01800-z", "study": "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study", "url": "https://doi.org/10.1186/s12933-023-01800-z"}, {"doi": "10.1186/s12933-025-02915-1", "study": "Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes", "url": "https://doi.org/10.1186/s12933-025-02915-1"}, {"doi": "10.1016/j.metop.2024.100283", "study": "Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study", "url": "https://doi.org/10.1016/j.metop.2024.100283"}, {"doi": "10.1177/17562864241281903", "study": "Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis", "url": "https://doi.org/10.1177/17562864241281903"}], "claim": "This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.", "claim_id": "claim_8"}, {"candidate_sources": [{"doi": "10.1155/jobe/3442754", "study": "Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration", "url": "https://doi.org/10.1155/jobe/3442754"}, {"doi": "10.1186/s12933-023-01800-z", "study": "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study", "url": "https://doi.org/10.1186/s12933-023-01800-z"}, {"doi": "10.1186/s12933-025-02915-1", "study": "Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes", "url": "https://doi.org/10.1186/s12933-025-02915-1"}, {"doi": "10.1016/j.metop.2024.100283", "study": "Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study", "url": "https://doi.org/10.1016/j.metop.2024.100283"}, {"doi": "10.1177/17562864241281903", "study": "Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis", "url": "https://doi.org/10.1177/17562864241281903"}], "claim": "The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.", "claim_id": "claim_9"}, {"candidate_sources": [{"doi": "10.1155/jobe/3442754", "study": "Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration", "url": "https://doi.org/10.1155/jobe/3442754"}, {"doi": "10.1186/s12933-023-01800-z", "study": "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study", "url": "https://doi.org/10.1186/s12933-023-01800-z"}, {"doi": "10.1186/s12933-025-02915-1", "study": "Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes", "url": "https://doi.org/10.1186/s12933-025-02915-1"}, {"doi": "10.1016/j.metop.2024.100283", "study": "Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study", "url": "https://doi.org/10.1016/j.metop.2024.100283"}, {"doi": "10.1177/17562864241281903", "study": "Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis", "url": "https://doi.org/10.1177/17562864241281903"}], "claim": "Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.", "claim_id": "claim_10"}, {"candidate_sources": [{"doi": "10.1155/jobe/3442754", "study": "Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration", "url": "https://doi.org/10.1155/jobe/3442754"}, {"doi": "10.1186/s12933-023-01800-z", "study": "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study", "url": "https://doi.org/10.1186/s12933-023-01800-z"}, {"doi": "10.1186/s12933-025-02915-1", "study": "Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes", "url": "https://doi.org/10.1186/s12933-025-02915-1"}, {"doi": "10.1016/j.metop.2024.100283", "study": "Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study", "url": "https://doi.org/10.1016/j.metop.2024.100283"}, {"doi": "10.1177/17562864241281903", "study": "Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis", "url": "https://doi.org/10.1177/17562864241281903"}], "claim": "Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.", "claim_id": "claim_11"}, {"candidate_sources": [{"doi": "10.1155/jobe/3442754", "study": "Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration", "url": "https://doi.org/10.1155/jobe/3442754"}, {"doi": "10.1186/s12933-023-01800-z", "study": "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study", "url": "https://doi.org/10.1186/s12933-023-01800-z"}, {"doi": "10.1186/s12933-025-02915-1", "study": "Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes", "url": "https://doi.org/10.1186/s12933-025-02915-1"}, {"doi": "10.1016/j.metop.2024.100283", "study": "Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study", "url": "https://doi.org/10.1016/j.metop.2024.100283"}, {"doi": "10.1177/17562864241281903", "study": "Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis", "url": "https://doi.org/10.1177/17562864241281903"}], "claim": "The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.", "claim_id": "claim_12"}, {"candidate_sources": [{"doi": "10.1155/jobe/3442754", "study": "Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration", "url": "https://doi.org/10.1155/jobe/3442754"}, {"doi": "10.1186/s12933-023-01800-z", "study": "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study", "url": "https://doi.org/10.1186/s12933-023-01800-z"}, {"doi": "10.1186/s12933-025-02915-1", "study": "Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes", "url": "https://doi.org/10.1186/s12933-025-02915-1"}, {"doi": "10.1016/j.metop.2024.100283", "study": "Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study", "url": "https://doi.org/10.1016/j.metop.2024.100283"}, {"doi": "10.1177/17562864241281903", "study": "Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis", "url": "https://doi.org/10.1177/17562864241281903"}], "claim": "Geroscience frames aging as a unitary biological process in which a discrete set of hallmark mechanisms — mitochondrial dysfunction, cellular senescence, deregulated nutrient sensing, stem-cell exhaustion, altered intercellular communication, and others — can be targeted to delay or compress morbidity and extend healthspan (canonical threshold anchors include Studenski 2011's 0.8 m/s gait-speed marker and Cruz-Jentoft 2019's 27 kg / 16 kg grip-strength cutoffs). This framework has regulatory implications: if aging itself is repositioned as a treatable condition, the field requires outcome measures that are sensitive to the tempo of functional decline and not solely to discrete disease events, a methodological caution reinforced by Ioannidis 2005 on surrogate endpoints. The present synthesis is anchored in GLP-1 — the proposal that glucagon-like peptide-1 receptor agonism, alone or combined with dual incretins, may shift trajectories on these aging-relevant endpoints. Across 52 curated references, however, the GLP-1 case is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and boundary conditions remain to be established.", "claim_id": "claim_13"}, {"candidate_sources": [{"doi": "10.1155/jobe/3442754", "study": "Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration", "url": "https://doi.org/10.1155/jobe/3442754"}, {"doi": "10.1186/s12933-023-01800-z", "study": "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study", "url": "https://doi.org/10.1186/s12933-023-01800-z"}, {"doi": "10.1186/s12933-025-02915-1", "study": "Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes", "url": "https://doi.org/10.1186/s12933-025-02915-1"}, {"doi": "10.1016/j.metop.2024.100283", "study": "Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study", "url": "https://doi.org/10.1016/j.metop.2024.100283"}, {"doi": "10.1177/17562864241281903", "study": "Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis", "url": "https://doi.org/10.1177/17562864241281903"}], "claim": "The preclinical and disease-model profile of incretin drugs, including dual and triple agonists, supplies the mechanistic plausibility for the Glp 1 hypothesis. Incretin pathways couple nutrient sensing to downstream cellular energetics, inflammation, and stress responses, intersecting several hallmarks central to geroscience (Mullur 2024). The corpus further suggests that pleiotropic actions on incretin drug signaling extend beyond glycemic control, with documented or hypothesized effects on blood pressure, lipid handling, and inflammatory tone (Zietek 2016; Rivera 2024). The receptor pharmacology underlying Glp 1 candidacy includes long-acting GLP-1 receptor agonists such as semaglutide, with structural homology to endogenous GLP-1 and extended half-life, and the dual GIP/GLP-1 receptor agonist tirzepatide (Alkhatib 2025; Schneck 2024). Nonetheless, the same corpus surfaces heterogeneity: observational and review-level evidence documents both favorable and null effects on intermediate cardiometabolic surrogates, suggesting that incretin drug mechanisms do not translate uniformly across all populations or comorbidity profiles.", "claim_id": "claim_14"}, {"candidate_sources": [{"doi": "10.1155/jobe/3442754", "study": "Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration", "url": "https://doi.org/10.1155/jobe/3442754"}, {"doi": "10.1186/s12933-023-01800-z", "study": "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study", "url": "https://doi.org/10.1186/s12933-023-01800-z"}, {"doi": "10.1186/s12933-025-02915-1", "study": "Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes", "url": "https://doi.org/10.1186/s12933-025-02915-1"}, {"doi": "10.1016/j.metop.2024.100283", "study": "Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study", "url": "https://doi.org/10.1016/j.metop.2024.100283"}, {"doi": "10.1177/17562864241281903", "study": "Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis", "url": "https://doi.org/10.1177/17562864241281903"}], "claim": "The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.", "claim_id": "claim_15"}, {"candidate_sources": [{"doi": "10.1155/jobe/3442754", "study": "Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration", "url": "https://doi.org/10.1155/jobe/3442754"}, {"doi": "10.1186/s12933-023-01800-z", "study": "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study", "url": "https://doi.org/10.1186/s12933-023-01800-z"}, {"doi": "10.1186/s12933-025-02915-1", "study": "Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes", "url": "https://doi.org/10.1186/s12933-025-02915-1"}, {"doi": "10.1016/j.metop.2024.100283", "study": "Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study", "url": "https://doi.org/10.1016/j.metop.2024.100283"}, {"doi": "10.1177/17562864241281903", "study": "Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis", "url": "https://doi.org/10.1177/17562864241281903"}], "claim": "Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.", "claim_id": "claim_16"}, {"candidate_sources": [{"doi": "10.1155/jobe/3442754", "study": "Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration", "url": "https://doi.org/10.1155/jobe/3442754"}, {"doi": "10.1186/s12933-023-01800-z", "study": "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study", "url": "https://doi.org/10.1186/s12933-023-01800-z"}, {"doi": "10.1186/s12933-025-02915-1", "study": "Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes", "url": "https://doi.org/10.1186/s12933-025-02915-1"}, {"doi": "10.1016/j.metop.2024.100283", "study": "Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study", "url": "https://doi.org/10.1016/j.metop.2024.100283"}, {"doi": "10.1177/17562864241281903", "study": "Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis", "url": "https://doi.org/10.1177/17562864241281903"}], "claim": "Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, dosing and pharmacokinetics, immune and inflammation, longevity, mortality and survival, muscle function, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.", "claim_id": "claim_17"}, {"candidate_sources": [{"doi": "10.1155/jobe/3442754", "study": "Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration", "url": "https://doi.org/10.1155/jobe/3442754"}, {"doi": "10.1186/s12933-023-01800-z", "study": "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study", "url": "https://doi.org/10.1186/s12933-023-01800-z"}, {"doi": "10.1186/s12933-025-02915-1", "study": "Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes", "url": "https://doi.org/10.1186/s12933-025-02915-1"}, {"doi": "10.1016/j.metop.2024.100283", "study": "Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study", "url": "https://doi.org/10.1016/j.metop.2024.100283"}, {"doi": "10.1177/17562864241281903", "study": "Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis", "url": "https://doi.org/10.1177/17562864241281903"}], "claim": "Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.", "claim_id": "claim_18"}, {"candidate_sources": [{"doi": "10.1155/jobe/3442754", "study": "Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration", "url": "https://doi.org/10.1155/jobe/3442754"}, {"doi": "10.1186/s12933-023-01800-z", "study": "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study", "url": "https://doi.org/10.1186/s12933-023-01800-z"}, {"doi": "10.1186/s12933-025-02915-1", "study": "Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes", "url": "https://doi.org/10.1186/s12933-025-02915-1"}, {"doi": "10.1016/j.metop.2024.100283", "study": "Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study", "url": "https://doi.org/10.1016/j.metop.2024.100283"}, {"doi": "10.1177/17562864241281903", "study": "Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis", "url": "https://doi.org/10.1177/17562864241281903"}], "claim": "| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |", "claim_id": "claim_19"}, {"candidate_sources": [{"doi": "10.1155/jobe/3442754", "study": "Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration", "url": "https://doi.org/10.1155/jobe/3442754"}, {"doi": "10.1186/s12933-023-01800-z", "study": "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study", "url": "https://doi.org/10.1186/s12933-023-01800-z"}, {"doi": "10.1186/s12933-025-02915-1", "study": "Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes", "url": "https://doi.org/10.1186/s12933-025-02915-1"}, {"doi": "10.1016/j.metop.2024.100283", "study": "Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study", "url": "https://doi.org/10.1016/j.metop.2024.100283"}, {"doi": "10.1177/17562864241281903", "study": "Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis", "url": "https://doi.org/10.1177/17562864241281903"}], "claim": "| Contextual Adjacent Evidence | n=16; claims=563 | no extracted directional signal in 10/16 sources | 9 indirect; 7 review | limited corpus depth in this outcome class |", "claim_id": "claim_20"}, {"candidate_sources": [{"doi": "10.1155/jobe/3442754", "study": "Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration", "url": "https://doi.org/10.1155/jobe/3442754"}, {"doi": "10.1186/s12933-023-01800-z", "study": "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study", "url": "https://doi.org/10.1186/s12933-023-01800-z"}, {"doi": "10.1186/s12933-025-02915-1", "study": "Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes", "url": "https://doi.org/10.1186/s12933-025-02915-1"}, {"doi": "10.1016/j.metop.2024.100283", "study": "Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study", "url": "https://doi.org/10.1016/j.metop.2024.100283"}, {"doi": "10.1177/17562864241281903", "study": "Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis", "url": "https://doi.org/10.1177/17562864241281903"}], "claim": "Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.", "claim_id": "claim_21"}, {"candidate_sources": [{"doi": "10.1155/jobe/3442754", "study": "Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration", "url": "https://doi.org/10.1155/jobe/3442754"}, {"doi": "10.1186/s12933-023-01800-z", "study": "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study", "url": "https://doi.org/10.1186/s12933-023-01800-z"}, {"doi": "10.1186/s12933-025-02915-1", "study": "Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes", "url": "https://doi.org/10.1186/s12933-025-02915-1"}, {"doi": "10.1016/j.metop.2024.100283", "study": "Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study", "url": "https://doi.org/10.1016/j.metop.2024.100283"}, {"doi": "10.1177/17562864241281903", "study": "Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis", "url": "https://doi.org/10.1177/17562864241281903"}], "claim": "Contextual Adjacent Evidence: n=16; claims=563; no extracted directional signal in 10/16 sources | directness: 9 indirect; 7 review; main limitation: no direct clinical anchor.", "claim_id": "claim_22"}, {"candidate_sources": [{"doi": "10.1155/jobe/3442754", "study": "Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration", "url": "https://doi.org/10.1155/jobe/3442754"}, {"doi": "10.1186/s12933-023-01800-z", "study": "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study", "url": "https://doi.org/10.1186/s12933-023-01800-z"}, {"doi": "10.1186/s12933-025-02915-1", "study": "Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes", "url": "https://doi.org/10.1186/s12933-025-02915-1"}, {"doi": "10.1016/j.metop.2024.100283", "study": "Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study", "url": "https://doi.org/10.1016/j.metop.2024.100283"}, {"doi": "10.1177/17562864241281903", "study": "Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis", "url": "https://doi.org/10.1177/17562864241281903"}], "claim": "Mechanistically, the cardiometabolic evidence in this corpus maps onto canonical GLP-1 receptor pathways including glycemic lowering, weight reduction, blood pressure decrement, and lipid modulation, which are most cleanly read in clinical RCT material such as Impact of GLP Receptor 2026 and in meta-analytic synthesis such as Rivera 2024. Crowley's case report (Crowley 2024) on lymphedema and Hashimoto 2025 on combined obesity-diabetes management extend the mechanistic substrate into adjacent cardiometabolic territory, while Fang 2026 reviews the dual GIP/GLP-1 agonist tirzepatide in obstructive sleep apnea as a downstream BMI-mediated cardiovascular lever, citing a near six-fold OSAS risk increment for every 10% BMI rise.", "claim_id": "claim_23"}, {"candidate_sources": [{"doi": "10.1155/jobe/3442754", "study": "Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration", "url": "https://doi.org/10.1155/jobe/3442754"}, {"doi": "10.1186/s12933-023-01800-z", "study": "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study", "url": "https://doi.org/10.1186/s12933-023-01800-z"}, {"doi": "10.1186/s12933-025-02915-1", "study": "Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes", "url": "https://doi.org/10.1186/s12933-025-02915-1"}, {"doi": "10.1016/j.metop.2024.100283", "study": "Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study", "url": "https://doi.org/10.1016/j.metop.2024.100283"}, {"doi": "10.1177/17562864241281903", "study": "Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis", "url": "https://doi.org/10.1177/17562864241281903"}], "claim": "Additional corpus sources included animal/preclinical evidence; within-corpus tensions in the cardiometabolic class are dense and must be read carefully. A second layer of conflict emerges between Rivera 2024's positive effect and the null directions reported by Randomisation to Endobarrier Alone 2017, Zhang 2024, Ghanim 2024, Mullur 2024, Alshehri 2025, Noordam 2025, Fang 2026, Bethel 2021, and Baviera 2022. A parallel layer separates the direct randomized evidence in Impact of GLP Receptor 2026 from the indirect observational and review evidence across the remaining source set, including Xu 2022, Piccini 2023, Coleman 2025, and PCOS 2022, an indirectness gap that should be preserved when integrating the cardiometabolic evidence base rather than collapsed across directness strata. (Detailed study-by-study endpoint values, including all p-values, are tabulated in the evidence synthesis.)", "claim_id": "claim_24"}, {"candidate_sources": [{"doi": "10.1155/jobe/3442754", "study": "Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration", "url": "https://doi.org/10.1155/jobe/3442754"}, {"doi": "10.1186/s12933-023-01800-z", "study": "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study", "url": "https://doi.org/10.1186/s12933-023-01800-z"}, {"doi": "10.1186/s12933-025-02915-1", "study": "Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes", "url": "https://doi.org/10.1186/s12933-025-02915-1"}, {"doi": "10.1016/j.metop.2024.100283", "study": "Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study", "url": "https://doi.org/10.1016/j.metop.2024.100283"}, {"doi": "10.1177/17562864241281903", "study": "Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis", "url": "https://doi.org/10.1177/17562864241281903"}], "claim": "Mechanistically, the contextual evidence base draws on three distinct substrate types. In a clinical RCT layer, Alkhatimalla-style pharmacokinetic characterization describes semaglutide as 94% structurally similar to endogenous GLP-1, with a half-life of 155–184 hours achieved by reduced metabolic clearance, and follow-up windows extending to 208 weeks in cited cohorts.", "claim_id": "claim_25"}, {"candidate_sources": [{"doi": "10.1155/jobe/3442754", "study": "Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration", "url": "https://doi.org/10.1155/jobe/3442754"}, {"doi": "10.1186/s12933-023-01800-z", "study": "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study", "url": "https://doi.org/10.1186/s12933-023-01800-z"}, {"doi": "10.1186/s12933-025-02915-1", "study": "Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes", "url": "https://doi.org/10.1186/s12933-025-02915-1"}, {"doi": "10.1016/j.metop.2024.100283", "study": "Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study", "url": "https://doi.org/10.1016/j.metop.2024.100283"}, {"doi": "10.1177/17562864241281903", "study": "Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis", "url": "https://doi.org/10.1177/17562864241281903"}], "claim": "The disagreement is most interpretable as endpoint-specific: Wu 2022 interrogates arrhythmia signals, whereas the conflicting null sources report on renal composites, behavioral outcomes, and stroke subtypes, each of which has a distinct biological substrate.", "claim_id": "claim_26"}, {"candidate_sources": [{"doi": "10.1155/jobe/3442754", "study": "Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration", "url": "https://doi.org/10.1155/jobe/3442754"}, {"doi": "10.1186/s12933-023-01800-z", "study": "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study", "url": "https://doi.org/10.1186/s12933-023-01800-z"}, {"doi": "10.1186/s12933-025-02915-1", "study": "Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes", "url": "https://doi.org/10.1186/s12933-025-02915-1"}, {"doi": "10.1016/j.metop.2024.100283", "study": "Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study", "url": "https://doi.org/10.1016/j.metop.2024.100283"}, {"doi": "10.1177/17562864241281903", "study": "Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis", "url": "https://doi.org/10.1177/17562864241281903"}], "claim": "The single included source addressing dosing and pharmacokinetics, Schneck 2024, is a population pharmacokinetic analysis of tirzepatide, a GIP/GLP receptor agonist administered subcutaneously in adults. The endpoint characterization centers on terminal half-life, exposure–response, and the once-weekly dosing schedule that follows the 4-week titration step. The canonical anchor for clinical dosing, as documented in the source, specifies that after 4 weeks the dose can be increased to 5 mg s.c. q.w., a transition that supports the sustained-exposure profile required for chronic administration. The study design is observational rather than interventional, and duration is framed by the population PK sampling strategy rather than a fixed follow-up window.", "claim_id": "claim_27"}, {"candidate_sources": [{"doi": "10.1155/jobe/3442754", "study": "Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration", "url": "https://doi.org/10.1155/jobe/3442754"}, {"doi": "10.1186/s12933-023-01800-z", "study": "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study", "url": "https://doi.org/10.1186/s12933-023-01800-z"}, {"doi": "10.1186/s12933-025-02915-1", "study": "Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes", "url": "https://doi.org/10.1186/s12933-025-02915-1"}, {"doi": "10.1016/j.metop.2024.100283", "study": "Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study", "url": "https://doi.org/10.1016/j.metop.2024.100283"}, {"doi": "10.1177/17562864241281903", "study": "Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis", "url": "https://doi.org/10.1177/17562864241281903"}], "claim": "Quantitative findings in Schneck 2024 converge on a half-life of approximately 5 days, a value that underwrites the once-weekly dosing interval. The source reports P < 0.01 and P < 0.001 as the model-derived significance markers supporting the exposure–response characterization, which jointly validate the sustained plasma profile observed across the dosing interval. These model-anchored results are reported without rounding or transformation in this synthesis. Because the source carries no clinical endpoint beyond PK modeling, the outcome class resolves entirely on pharmacokinetic rather than efficacy metrics.", "claim_id": "claim_28"}, {"candidate_sources": [{"doi": "10.1155/jobe/3442754", "study": "Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration", "url": "https://doi.org/10.1155/jobe/3442754"}, {"doi": "10.1186/s12933-023-01800-z", "study": "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study", "url": "https://doi.org/10.1186/s12933-023-01800-z"}, {"doi": "10.1186/s12933-025-02915-1", "study": "Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes", "url": "https://doi.org/10.1186/s12933-025-02915-1"}, {"doi": "10.1016/j.metop.2024.100283", "study": "Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study", "url": "https://doi.org/10.1016/j.metop.2024.100283"}, {"doi": "10.1177/17562864241281903", "study": "Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis", "url": "https://doi.org/10.1177/17562864241281903"}], "claim": "Within-corpus tensions on dosing and pharmacokinetics are limited to a single source, so no pairwise disagreements can be surfaced for this outcome class. By contrast, the broader corpus places cardiometabolic, body composition, and glycemic outcomes downstream of the PK envelope that Schneck 2024 establishes, and the indirectness flag functions as the integration point rather than as a contradiction. The PK finding of sustained exposure therefore reads as a permissive upstream condition rather than as direct longevity evidence, consistent with the integrating thesis that mechanistic plausibility coexists with mixed or sparse human-RCT evidence.", "claim_id": "claim_29"}, {"candidate_sources": [{"doi": "10.1155/jobe/3442754", "study": "Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration", "url": "https://doi.org/10.1155/jobe/3442754"}, {"doi": "10.1186/s12933-023-01800-z", "study": "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study", "url": "https://doi.org/10.1186/s12933-023-01800-z"}, {"doi": "10.1186/s12933-025-02915-1", "study": "Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes", "url": "https://doi.org/10.1186/s12933-025-02915-1"}, {"doi": "10.1016/j.metop.2024.100283", "study": "Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study", "url": "https://doi.org/10.1016/j.metop.2024.100283"}, {"doi": "10.1177/17562864241281903", "study": "Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis", "url": "https://doi.org/10.1177/17562864241281903"}], "claim": "The corpus contains a single observational cohort study, Zietek 2016, that directly frames inflammation as a convergence point between metabolic disease and enteroendocrine biology. The study population is described as adults, and the design is observational rather than interventional, which constrains causal inference about GLP-1 signaling on inflammatory endpoints. The cited thesis foregrounds enteroendocrine cells (EEC) as a numerically sparse but hormonally rich compartment, noting they comprise approximately only 1% of the epithelium yet secrete more than 20 different peptide hormones. This anatomical and quantitative baseline establishes the cellular substrate from which downstream immune and metabolic effects of GLP-1 are hypothesized to propagate. No effect direction is recorded for inflammatory endpoints in the source, consistent with a null designation at the level of direct measurement.", "claim_id": "claim_30"}]}

metadata

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "2b3d1eb0-8efe-4468-b234-8a534f83b06b",
  "researka_submission_id": "55294f57-700e-484d-8893-908a24c86e60",
  "sidecar_name": "citation_traces.json",
  "sidecar_url": "https://api.researka.org/publications/2b3d1eb0-8efe-4468-b234-8a534f83b06b/sidecars/citation_traces.json"
}

view full chain →